-
Screening for pre-eclampsia using sFlt-1/PlGF ratio cut-off of 38 at 30-37 weeks' gestation.
Dragan I, Georgiou T, Prodan N, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:73-77. pdf -
Maternal cardiac function at 35-37 weeks' gestation: relationship with birth weight.
Guy GP, Ling HZ, Machuca M, Poon LC, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:67-72. pdf -
Maternal cardiac function at 35-37 weeks' gestation: prediction of pre-eclampsia and gestational hypertension.
Guy GP, Ling HZ, Garcia P, Poon LC, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:61-66. pdf -
Maternal cardiovascular function at 35-37 weeks' gestation: Relation to maternal characteristics.
Guy GP, Ling HZ, Garcia P, Poon LC, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:39-45. pdf -
Development of preeclampsia within four weeks of sFLT to PLGF ratio >38: Comparison of performance at 31-34 versus 35-37 weeks' gestation.
Dragan I, Wright D, Fiolna M, Leipold G, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:209-12. pdf -
Can Staining of Damaged Proteins in Urine Effectively Predict Preeclampsia?
Sammar M, Syngelaki A, Sharabi-Nov A, Nicolaides K, Meiri H.
Fetal Diagn Ther 2017;41:23-31. pdf -
Metabolomic determination of pathogenesis of late-onset preeclampsia.
Bahado-Singh RO, Syngelaki A, Mandal R, Graham SF, Akolekar R, Han B, Bjondahl TC, Dong E, Bauer S, Alpay-Savasan Z, Turkoglu O, Ogunyemi D, Poon LC, Wishart DS, Nicolaides KH.
J Matern Fetal Neonatal Med 2017;30:658-64. pdf -
The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis.
Roberge S, Nicolaides K, Demers S, Hyett J, Chaillet N, Bujold E.
Am J Obstet Gynecol 2017;216:110-120.e6. pdf -
Comparison of screening for pre-eclampsia at 31-34 weeks' gestation by sFlt-1/PlGF ratio and a method combining maternal factors with sFlt-1 and PlGF.
Tan MY, Wright D, Koutoulas L, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:201-8. pdf -
Proposed clinical management of pregnancies after combined screening for pre-eclampsia at 30-34 weeks' gestation.
Wright D, Dragan I, Syngelaki A, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:194-200. pdf -
Study protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with ASpirin for evidence-based PREeclampsia prevention (ASPRE)
O'Gorman N, Wright D, Rolnik DL, Nicolaides KH, Poon LC.
BMJ Open 2016;6:e011801. pdf -
Competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 35-37 weeks' gestation.
Andrietti S, Silva M, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;48:72-9. pdf -
Maternal serum PAPP-A and free beta-hCG at 12, 22 and 32 weeks' gestation in screening for pre-eclampsia.
Wright A, Guerra L, Pellegrino M, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:762-7. pdf -
Maternal serum soluble fms-like tyrosine kinase-1 at 22 and 32 weeks in the prediction of pre-eclampsia.
Wright D, Krajewska K, Bogdanova A, Wright A, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:755-61. pdf -
Mean arterial pressure at 12, 22, 32 and 36 weeks' gestation in screening for pre-eclampsia.
Tayyar A, Krithinakis K, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:573-9. pdf -
Uterine artery pulsatility index at 12, 22, 32 and 36 weeks' gestation in screening for pre-eclampsia.
O'Gorman N, Tampakoudis G, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:565-72. pdf -
Contingent screening for preterm pre-eclampsia.
Wright D, Gallo DM, Gil Pugliese S, Casanova C, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:554-9. pdf -
Prevention of pre-eclampsia by low-molecular-weight heparin in addition to aspirin: a meta-analysis.
Roberge S, Demers S, Nicolaides KH, Bureau M, Côté S, Bujold E.
Ultrasound Obstet Gynecol 2016;47:548-53. pdf -
Maternal serum soluble fms-like tyrosine kinase-1 at 12, 22, 32 and 36 weeks' gestation in screening for pre-eclampsia.
Tsiakkas A, Mendez O, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:478-83. pdf -
Maternal serum placental growth factor at 12, 22, 32 and 36 weeks' gestation in screening for pre-eclampsia.
Tsiakkas A, Cazacu R, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:472-7. pdf